Delivery Order SPE2DB25D3404-SPE2DB25FUQCD
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections (0.5 mL units) with a ceiling value of $1,659.37. This firm fixed-price delivery order, which is set to be completed by August 15, 2025, will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a non-competitive delivery order issued under AmerisourceBergen's existing indefinite delivery...
- The Defense Logistics Agency awarded a $58,304.44 delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Zepbound 10 mg/0.5 mL pens. The contract is a firm fixed-price delivery order with an ultimate completion date of August 4, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. This award carries no set-aside designation and was competitively awarded under an existing contract vehicle. AmerisourceBergen Drug Corp is a major...
- The Defense Logistics Agency awarded a delivery order valued at $9,727.53 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on August 12, 2025, with completion due by August 13, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued competitively under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Zepbound 5 mg/0.5 ml pens, with a contract value of $6,827.77 and completion deadline of August 22, 2025. This is a firm fixed-price, non-set-aside delivery order classified as a child contract, indicating it was issued under a larger indefinite delivery vehicle. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens in 0.5 mL quantities, with a ceiling value of $7,625.80. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The order is scheduled for...
- The Defense Logistics Agency awarded a delivery order valued at $6,750.31 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,233.41 to AmerisourceBergen Drug Corp for the supply of Zepbound 12.5 mg/0.5 mL pens on July 31, 2025, with completion scheduled for August 1, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $28,634.71 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pen injectors on August 11, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999, which runs through December 2026. The performance location is the company's corporate office in Conshohocken, Pennsylvania, with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Zepbound 10 mg/0.5 ml pens in 0.5 ml quantities, valued at $14,093.41. This firm fixed-price delivery order, with an ultimate completion date of August 20, 2025, represents a competitively awarded contract with no set-aside designation. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound 5 mg/0.5 mL pens valued at $3,050.32 with a completion date of August 18, 2025. This is a firm fixed-price delivery order with no set-aside designation, executed under open competition. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger...
- SPE2DB25D3404Indefinite Delivery Contract
- SPE2DB25D3404-SPE2DB25FUQCDDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,596.11 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on August 27, 2025, with completion expected by August 28, 2025. This competitively awarded, firm fixed-price contract represents a single delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The award falls under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as a global pharmaceutical support vehicle for military healthcare programs. This delivery order exemplifies AmerisourceBergen Drug Corp's ongoing role as a critical vendor in the federal medical supply chain, supplying pharmaceutical products to support Defense Health Agency and other government healthcare systems. Zepbound, a GLP-1 receptor agonist used for weight management, represents the company's capability to provide specialized medications across multiple therapeutic domains. The modest contract value and expedited completion timeline reflect routine pharmaceutical replenishment operations within the broader framework of the company's comprehensive indefinite delivery contract, which enables flexible fulfillment of federal medical supply needs across therapeutic categories including diabetes medications, neurological treatments, and other specialized healthcare commodities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.6k | 8/27/25 |